Evidence map›Paper›PMID 40548990›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2025

Predictive value of [

Yaqun Jiang, Zili Yu, Yanan Sun, Yueli Tian, Li Wang, Diankui Xing, Yiwei Huang, Yong He, Jun Jia

2 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05030597 unknown statusnot on this map

Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma

TypeobservationalSponsorZhongnan HospitalRan2021 to 2025Enrolled100ConditionsPET/CT, FAPI, Oral CancerArms68Ga-DOTA-FAPI, PET/CT, Participants receive baseline paired FDG and FAPI PET/CT. For resectable locally advanced cases receiving neoadjuvant therapy undergo follow-up FAPI PET imaging.
NCT05034146 narecruitingnot on this map

The Diagnostic Efficiency of 68Ga-FAPI PET/CT in Malignant Tumors

TypeinterventionalSponsorZhongnan HospitalRan2021 to 2025Enrolled500ConditionsFibroblast Activation Protein Inhibitor, PET/CT, Malignant NeoplasmArms68Ga-FAPI, PET/CT
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yaqun Jiang *Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.ORCID 0000-0003-0933-4528
Zili Yu *Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
Yanan SunOral Histopathology Department, School and Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
Yueli TianDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Li WangOral Histopathology Department, School and Hospital of Stomatology, Wuhan University, Wuhan, 430079, China.
Diankui XingDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Yiwei HuangDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Yong HeDepartment of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. vincentheyong@163.com.ORCID 0000-0002-9846-7578
Jun JiaDepartment of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, 430079, China. junjia@whu.edu.cn.

Funding

Hubei Provincial Natural Science Foundation 2024AFB725National Natural Science Foundation of China 82302245National Natural Science Foundation of China 82372005Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund CXPY2023012
6 · The paper itself

Abstract

purposeThis prospective study aimed to investigate the performance of [

methodsThirty-one treatment-naïve OSCC patients (stage III-IVA) scheduled to receive two cycles of NACI followed by radical surgery were enrolled. [

resultsTwenty patients were included in the final analysis. Eight patients (40.0%) achieved major pathological response (MPR), including 6 with pathologic complete response (pCR), while 12 patients (60.0%) were categorized as non-MPR according to postoperative histopathological findings. The average preoperative SUVmax was significantly lower in the MPR group (9.38 ± 2.60) compared with that in the non-MPR group (16.20 ± 5.23; P = 0.003), while baseline SUVmax was not significantly different (P = 0.053). The ∆SUVmax (%) in the MPR group (- 59.10% ± 13.33) was notably lower than that in the non-MPR group (- 15.96%, [- 52.56%, 66.33%]; P = 0.002). Preoperative SUVs and ∆SUVs were significantly associated with pathologic response. FAP expression was positively correlated with preoperative SUVs, and the MPR group showed higher CD8 and GZMB expression versus the non-MPR group.

conclusion[ CLINICAL

trial registrationThis prospective study was reviewed and approved by the Medical Ethics Committee of Zhongnan Hospital, Wuhan University, and was registered online at NIH ClinicalTrials.gov (NCT05034146 & NCT05030597).

Indexed as

Carcinoma, Squamous CellImmunotherapyMouth NeoplasmsNeoadjuvant TherapyPositron Emission Tomography Computed TomographyAdultAgedFemaleGallium RadioisotopesHumansMaleMiddle AgedPredictive Value of TestsQuinolinesTreatment Outcome68Ga-FAPIGallium RadioisotopesQuinolines[68Ga]Ga-FAPI-04Neoadjuvant chemoimmunotherapyOral squamous cell carcinomaPathologic responsePET/CT

Identifiers

PMID40548990

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.